Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		$ 483.7	$ 454.9	$ 925.9	$ 877.9
Segment EBITDA		85.2	97.4	147.9	169.6
Inter-segment revenue elimination		(9.2)	(7.2)	(19.7)	(19.4)
Unallocated Costs	[1]	(19.8)	(12.9)	(40.1)	(26.8)
Impairment Charges And Gain Loss On Sale Of Assets		0.5	(0.1)	0.5	1.1
Equity compensation		(4.9)	(2.6)	(11.8)	(5.1)
Restructuring and other special items	[2]	(7.2)	(4.2)	(13.1)	(6.2)
Noncontrolling interest		0.0	0.1	0.0	0.3
Other income (expense), net	[3]	1.8	3.5	3.9	2.9
Non-allocated corporate costs, net		(9.0)	(9.8)	(18.6)	(17.6)
Total unallocated costs	[1]	(19.8)	(12.9)	(40.1)	(26.8)
Softgel Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		201.9	181.1	388.3	365.1
Segment EBITDA		43.4	34.8	73.9	69.4
Drug Delivery Solutions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		214.0	204.1	405.3	377.7
Segment EBITDA		50.0	62.1	92.0	99.6
Clinical Supply Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		77.0	76.9	152.0	154.5
Segment EBITDA		$ 11.6	$ 13.4	$ 22.1	$ 27.4

[1] Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, certain other corporate directed costs, certain customer claim expenses related to the Beinheim facility suspension and other costs that are not allocated to the segments as follows:

[2] Segment results do not include restructuring and other costs associated with certain customer claim expenses related to the Beinheim facility suspension and certain acquisition-related costs.

[3] Amounts primarily relate to foreign currency translation gains and losses during all periods presented.